Share Name Share Symbol Market Type Share ISIN Share Description
Bb Healthcare Trust Plc LSE:BBH London Ordinary Share GB00BZCNLL95 RED ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 195.00 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
195.00 195.60
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3.66 1.14 0.14 1,392.9 1,046
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 195.00 GBX

Bb Healthcare (BBH) Latest News

More Bb Healthcare News
Bb Healthcare Investors    Bb Healthcare Takeover Rumours

Bb Healthcare (BBH) Discussions and Chat

Bb Healthcare Forums and Chat

Date Time Title Posts
09/4/202115:31::: B B HEALTHCARE TRUST :::63
12/7/200616:01Biotech Holders: the last to Run?15

Add a New Thread

Bb Healthcare (BBH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-24 16:12:28195.006,92913,511.55O
2021-06-24 16:12:13195.0013,85827,023.10O
2021-06-24 16:03:38193.041,0361,999.90O
2021-06-24 15:35:20195.00227,133442,909.35UT
2021-06-24 15:30:00195.06512998.70O
View all Bb Healthcare trades in real-time

Bb Healthcare (BBH) Top Chat Posts

Bb Healthcare Daily Update: Bb Healthcare Trust Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker BBH. The last closing price for Bb Healthcare was 195p.
Bb Healthcare Trust Plc has a 4 week average price of 180.20p and a 12 week average price of 177.80p.
The 1 year high share price is 202.50p while the 1 year low share price is currently 152p.
There are currently 536,574,403 shares in issue and the average daily traded volume is 1,058,165 shares. The market capitalisation of Bb Healthcare Trust Plc is £1,046,320,085.85.
speedsgh: Citywire podcast (40m31s). Transcript of podcast also available lower down the page on the following link... Covid-19: What does the future of vaccination look like now? - HTTPS:// Citywire’s Gavin Lumsden talks to Paul Major, fund manager of BB Healthcare (BBH) investment trust; Dr Annalisa Jenkins, former chief executive of Dimension Therapeutics; and Professor Justin Stebbing, professor of cancer medicine and oncology at Imperial College London and a non-executive director of BBH, about the scientific, political and societal challenges in keeping coronavirus at bay. This is the second in a series of three Funds Fanatic podcasts in association with BB Healthcare. The first looked at the ‘global collaboration that will help us defeat Covid-19’ - HTTPS://
jonwig: Thankls Eberhardt - if you register you get two free articles a week (that's good enough for me usually: BB Healthcare Trust reckons last month’s market sell-off is too much of an opportunity to miss. The investment trust pressed ahead with a share issue programme yesterday that could mean it raises more than its current market value over the next 12 months. It argued that the October fall in prices had a disproportionately high effect on the kinds of smaller, high-growth companies it invests in and there are stockpicking deals to be had. BB Healthcare may actually be one itself. Its shares have lost 9 per cent since the beginning of October, against a drop of 4.5 per cent in the wider MSCI Healthcare index that it benchmarks itself against. The company is worth a closer look. BB Healthcare was listed in December 2016 and is managed by Bellevue Asset Management, a Swiss-based group that came up with the idea of a specialist healthcare investment trust after it encountered investment constraints with an existing, much larger biotech fund. Its brief is to invest in listed healthcare companies worldwide based on no criteria other than potential future value. It has limited itself to a maximum of 35 holdings and in practice 94 per cent of its portfolio is with American companies, hardly surprising given the entrepreneurial role of the private sector in healthcare provision with a regulator that is keen to foster innovation in treatments. Among its largest investments is Anthem, a health insurance company formerly known as Wellpoint; Teladoc, a phone-based healthcare provider; and Illumina, a technology-driven group whose products are used in genetic analysis. The fund tries to ensure all of its funds are invested at any one time but regularly issues new stock to fund growth, unafraid to quadruple its size in the coming years from its current £430 million. Its facility yesterday authorised it to issue as many as 345 million new shares over the next 12 months, worth a little more than £470 million, based on yesterday’s price, up 1p to 135½p. Its strategy of investing in huge structural changes in worldwide health provision against the backdrop of our longer lives, better treatments for chronic diseases and the rise of private care is interesting. ADVICE Buy for the long term WHY Proven in profiting from healthcare’s structural changes
eberhardt: According Tempus in The Times today BBH is a buy for the long term. Not a subscriber so can't give full link. Reported in the news summary in Citywire hxxps://
jonwig: Issue of equity, including placing, open offer, intermediaries offer: "The issue price per Ordinary Share of any shares issued pursuant to the Initial Issue will be at a premium of 2% to the unaudited NAV per Ordinary Share (cum income) on the day that the Initial Placing closes, which is expected to be 28 November 2018. "
toffeeman: they are too small for BBH
semper vigilans: Would be good for all concerned if BBH invested in AGL & AOR if it hasn’t done so already. Performance v. good anyway!
jonwig: Comment on BBH after the annual results: Http:// Maybe answers your question, Toffeeman!
jonwig: BBH a part of this article: Http://
jonwig: Latest NAV 111p so new shares would notionally be offered at ~112.7p. But if NAV fall is due to USD, it could continue and the offer overtaken by events. Can probably wait until noon tomorrow as unlikely to be over-subscribed, I think. Issue price is determined as cum-inc NAV at today's close plus 1.5%. Unfortunately that won't be published until mid-afternoon tomorrow, so best estimate is yesterday's closing NAV to be published this afternoon.
jonwig: Page 12: The price at which new Ordinary Shares will be issued pursuant to the Second Issue will be calculated by reference to the prevailing NAV (cumincome) of the existing Ordinary Shares together with a premium of 1.5 per cent. intended to cover the costs and expenses of the Second Issue (including, without limitation, placing commissions). However, for illustrative purposes only, assuming that 25,484,200 Ordinary Shares are issued pursuant to the Second Issue and an issue price of 117.72 pence per new Ordinary Share ... Page 14: Under the Intermediaries Offer, the Ordinary Shares are being offered to Intermediaries in the United Kingdom, the Channel Islands and the Isle of Man who will facilitate the participation of their retail investor clients located in the United Kingdom, the Channel Islands and the Isle of Man. A minimum subscription amount of £1,000 per Underlying Applicant will apply. Completed Applications from Intermediaries must be received by Peel Hunt no later than 3.00 p.m. on 20 September 2017.
Bb Healthcare share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Bb Healthc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210625 06:02:57